Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 18/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.58 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.56 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.56 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.56 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.56 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
| ▸ | STK16 | O75716 | 1/20 | 0.56 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464190 | 0.91 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL12013958 | 0.89 | PIK3CA (0.63) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL13640251 | 0.89 | PIK3CD (0.59) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL2431983 | 0.88 | PIK3CD (0.60) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL2468095 | 0.87 | PIK3CD (0.57) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL12013712 | 0.87 | PIK3CD (0.61) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL2469473 | 0.87 | PIK3CD (0.62) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL1088587 | 0.85 | PIK3CA (0.81) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL3624259 | 0.85 | PIK3CD (0.78) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL3619087 | 0.84 | PIK3CD (0.82) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | claimed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | claimed |
| US-8252792-B2 | Pyrimidine derivatives as PI3K inhibitors | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-28 | — | — | US | claimed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | claimed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-8252792-B2 | Pyrimidine derivatives as PI3K inhibitors | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-8252792-B2 | Pyrimidine derivatives as PI3K inhibitors | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-8252792-B2 | Pyrimidine derivatives as PI3K inhibitors | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-28 | — | — | US | disclosed |
| EP-2365810-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010065923-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | disclosed |
| WO-2007122410-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3R5 | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 6/4885 |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.